Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10174139 | 0.96 | GAA (0.44) | EPHX2HRH3GAAKDM4EALDH1A1 | |
| SCHEMBL17482090 | 0.96 | GAA (0.44) | EPHX2HRH3GAAKDM4EALDH1A1 | |
| SCHEMBL15426235 | 0.88 | GAA (0.40) | EPHX2HRH3GAAKDM4EALDH1A1 | |
| SCHEMBL10174121 | 0.78 | ALDH1A1 (0.54) | GAAKDM4EALDH1A1HPGDATM | |
| SCHEMBL12804795 | 0.76 | CD274 (0.48) | HRH3GAAKDM4EALDH1A1HPGD | |
| SCHEMBL15426234 | 0.75 | GAA (0.46) | EPHX2HRH3GAAKDM4EALDH1A1 | |
| SCHEMBL10193853 | 0.75 | GAA (0.46) | EPHX2HRH3GAAKDM4EALDH1A1 | |
| SCHEMBL10193803 | 0.75 | HRH3 (0.59) | EPHX2CYP1A2CYP2D6HRH3ALDH1A1 | |
| SCHEMBL10174122 | 0.73 | POLB (0.52) | EPHX2HRH3KDM4EALDH1A1KMT2A | |
| SCHEMBL10174114 | 0.73 | ALDH1A1 (0.54) | EPHX2HRH3GAAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9212142-B2 | Niacin mimetics, and methods of use thereof | TRUSTEES OF TUFTS COLLEGE (US) | 2015-12-15 | — | — | US | disclosed |
| US-20140018359-A1 | Niacin Mimetics, and Methods of Use Thereof | Arisaph Pharmaceuticals (US) | 2014-01-16 | — | — | US | disclosed |
| US-8450316-B2 | Niacin mimetics, and methods of use thereof | TRUSTEES OF TUFTS COLLEGE (US) | 2013-05-28 | — | — | US | disclosed |
| US-20120077807-A1 | NIACIN MIMETICS, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018359-A1 | Niacin Mimetics, and Methods of Use Thereof | NAMPT, NNT, NAPRT | EPHX2 1894/4885CYP1A2 456/4885CYP2D6 340/4885 |
| US-20120077807-A1 | NIACIN MIMETICS, AND METHODS OF USE THEREOF | NAMPT, NNT, NAPRT | EPHX2 1894/4885CYP1A2 456/4885CYP2D6 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.